Results 11 to 20 of about 2,191 (125)
The Oncologist, EarlyView., 2021 Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom +11 more
wiley +1 more source
Current Oncology, 2023 Recently, selpercatinib, a highly selective inhibitor of RET receptor tyrosine kinase, has been used for RET-altered thyroid cancer. We present four cases of patients with advanced thyroid cancer who were treated with selpercatinib. The first patient was
Han-Sang Baek +5 more
doaj +1 more source
The Oncologist, EarlyView., 2021 Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth +10 more
wiley +1 more source
Radioiodine-Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy. [PDF]
Cancer InnovRadioiodine‐refractory differentiated thyroid cancer (RAIR‐DTC) management now spans selective kinase inhibitors, MAPK‐pathway redifferentiation, VEGFR multikinase TKIs, and biomarker‐driven immunotherapy. We propose a three‐axis decision framework integrating molecular driver, evidence level, and patient dimension to guide individualized treatment ...
Li Y, He Z.
europepmc +2 more sources
Frontiers in Oncology, 2023 The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug’s approval for this indication ...
Jonathan W. Goldman +10 more
doaj +1 more source
Respirology Case Reports, 2023 An 83‐year‐old woman with RET fusion‐positive advanced lung adenocarcinoma was administered selpercatinib 320 mg/day. Despite the shrinking of the tumour, fever, fatigue, and anorexia developed on day 17. Selpercatinib administration was interrupted.
Kazuhisa Nakashima +9 more
doaj +1 more source
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
npj Precision Oncology, 2021 Recently Food and Drug Administration (FDA)-approved pralsetinib (BLU-667) and selpercatinib (LOXO-292) are RET-selective protein tyrosine kinase inhibitors for treating RET-altered cancers, but whether they have distinct activity was unknown.
Tao Shen +5 more
doaj +1 more source
Current Oncology, 2022 Selpercatinib, a RET kinase inhibitor, is an effective treatment for patients with medullary thyroid cancer with RET mutations. In this paper, we present the case of a 62-year-old man with ectopic Cushing’s syndrome due to medullary thyroid cancer who ...
Oskar Ragnarsson +2 more
doaj +1 more source
Case Reports in Oncology, 2022 Standard treatment for unresectable papillary thyroid carcinoma (PTC) is a multi-kinase inhibitor, including lenvatinib and sorafenib. Rearranged during transfection (RET) fusions are found in approximately 10% of PTC.
Tomoya Yokota
doaj +1 more source
Frontiers in Oncology, 2023 RET fusions occur in 1–2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective RET inhibitors with significant improvement of outcome in patients with tumor harboring RET fusion; however, resistance mechanisms appear frequently ...
Caio Abner Leite +6 more
doaj +1 more source